Important note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.
 |
Voice of America - November 10, 2008
Carole Gombakomba
Washington
The Global Fund to Fight AIDS, Tuberculosis and Malaria on Monday promised Zimbabwe US$169 million in its eighth round of funding, finalized over the weekend by the board of the international health organization at a meeting in New Delhi, India.
Many in Zimbabwe had feared that the country would be refused new funding because the Reserve Bank of Zimbabwe mishandled funds given to Zimbabwe in previous Global Fund rounds. But the central bank returned the US$7.3 million last week after coming under international scrutiny for misusing those and other donor funds.
HIV/AIDS activist Martha Tholana told VOA that while the local community is pleased with the Global Fund decision, vigilance is called for in their handling in future.
Tholana added that the country's health care system remains in critical condition, because monies from the Global Fund earmarked for AIDS, tuberculosis and malaria, while even leading state hospitals in Harare are closing wards due to the economic crisis.
VOA was unable to reach Health Minister David Parirenyatwa for comment.
Global Fund Communications Director John Liden told reporter Carole Gombakomba of VOA's Studio 7 for Zimbabwe that the latest funds pledged to Zimbabwe have conditions attached to them to avoid future problems at the central bank.
081104
VA081103
Copyright © 2008 - Voice of America. You are welcome to use any material that is published by voanews.com, or you may link to any of the web pages that Voice of America has published on the internet. There is no need to request further permission. Should you wish to establish a link to any VOA web pages, please send your request to pubaff@ibb.gov. We would appreciate that credit for any use of VOA material be given to voanews.com, Voice of America, or VOA, and we ask that you not abridge or edit any VOA material which you may use.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .